First-line bevacizumab (B) plus paclitaxel (P) in HER2-negative (HER2-ve) metastatic breast cancer (mBC): Efficacy and safety in an Italian multicenter retrospective study

被引：0
|
作者：
Andreis, D.
Scandurra, G.
Santini, D.
Gucciardino, C.
La Verde, N. M.
Girelli, S.
Alabiso, I.
Saetta, A.
Atzori, F.
Collova, E.
Ferzi, A.
Gori, S.
Lipari, H.
Saggia, C.
Marcon, I.
Generali, D. G.
机构：
[1] AO Ist Ospitalieri Cremona, UO Multidisciplinare Patol Mammaria, Cremona, Italy
[2] Day Hop, Humanitas Ctr Catanese Oncol, Catania, Italy
[3] Univ Campus Biomed Roma, Dipartimento Med Oncol, Rome, Italy
[4] AO Fatebenefratelli & Oftalm, UO Oncol Med, Milan, Italy
[5] Univ Turin, Dipartimento Sci Clin & Biol, Turin, Italy
[6] Fdn Ist San Raffaele D Giglio di Cefalu, UO Oncol, Cefalu, Italy
[7] AOU Cagliari, Struttura Complessa Oncol Med, Cagliari, Italy
[8] Osped Civile Legnano, Legnano, Italy
[9] AO Perugia, Oncol Med, Perugia, Italy
[10] Cannizzaro Hosp, Div Med Oncol, Catania, Italy
[11] AOU Osped Maggiore della Carita, SCDU Oncol, Novara, Italy
[12] AO Osped Circolo, UO Oncol, Varese, Italy
[13] Fdn Macchi, Varese, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.e11502
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e11502
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase II study of bevacizumab (Bev) combined with weekly paclitaxel (wPac) as first-line therapy for Japanese patients (pts) with HER2-negative metastatic breast cancer (MBC).
    Masuda, N.
    Aogi, K.
    Ohno, S.
    Iwata, H.
    Kashiwaba, M.
    Fujiwara, Y.
    Ito, Y.
    Ueno, T.
    Saijo, N.
    Takashima, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [32] Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer
    J. Salvador
    L. Manso
    J. de la Haba
    A. Jaen
    E. Ciruelos
    M. C. de Villena
    M. Gil
    A. Murias
    A. Galan
    C. Jara
    J. Bayo
    J. M. Baena
    J. Casal
    J. R. Mel
    I. Blancas
    P. Sanchez Rvira
    Clinical and Translational Oncology, 2015, 17 : 160 - 166
  • [33] Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer
    Salvador, J.
    Manso, L.
    de la Haba, J.
    Jaen, A.
    Ciruelos, E.
    de Villena, M. C.
    Gil, M.
    Murias, A.
    Galan, A.
    Jara, C.
    Bayo, J.
    Baena, J. M.
    Casal, J.
    Mel, J. R.
    Blancas, I.
    Sanchez Rvira, P.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2015, 17 (02): : 160 - 166
  • [34] First-Line Bevacizumab (Bev) Combined With Paclitaxel (pac) In Older Patients (pts) Treated for HER2-Negative Metastatic Breast Cancer (mBC) in a Routine Oncology Practice Study
    Foerster, F.
    Aktas, B.
    Geberth, M.
    Tschechne, B.
    Schneeweiss, A.
    Salat, C.
    Tesch, H.
    Welslau, M.
    Schmidt, M.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S351 - S352
  • [35] Randomized Phase III Study of First-line Bevacizumab in Combination With Capecitabine or Paclitaxel for HER2-negative LR/MBC: Interim Safety Data
    Inbar, M.
    Lang, I.
    Kahan, Z.
    Greil, R.
    Beslija, S.
    Stemmer, S. M.
    Kaufman, B.
    Zvirbule, Z.
    Steger, G. G.
    Zielinski, C. C.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S346 - S346
  • [36] Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France
    Petitjean, Audrey
    Smith-Palmer, Jayne
    Valentine, William
    Tehard, Bertrand
    Roze, Stephane
    BMC CANCER, 2019, 19 (1)
  • [37] Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France
    Audrey Petitjean
    Jayne Smith-Palmer
    William Valentine
    Bertrand Tehard
    Stephané Roze
    BMC Cancer, 19
  • [38] Nab-paclitaxel plus bevacizumab in heavily pretreated HER2-negative metastatic breast cancer
    Miano, S. T.
    Rossi, G.
    Marsili, S.
    Petrioli, R.
    Pascucci, A.
    Francini, G.
    ANNALS OF ONCOLOGY, 2015, 26 : 22 - 23
  • [39] New schedule of bevacizumab/paclitaxel as first-line therapy for metastatic HER2-negative breast cancer in a real-life setting
    Cannita, Katia
    Paradisi, Stefania
    Cocciolone, Valentina
    Bafile, Alberto
    Rinaldi, Lucia
    Irelli, Azzurra
    Baldi, Paola Lanfiuti
    Zugaro, Luigi
    Manetta, Rosa
    Alesse, Edoardo
    Ricevuto, Enrico
    Ficorella, Corrado
    CANCER MEDICINE, 2016, 5 (09): : 2232 - 2239
  • [40] First-Line Bevacizumab in Combination with Capecitabine or Paclitaxel for HER2-Negative Locally Recurrent or Metastatic Breast Cancer (LR/MBC): A Randomized Phase Ill Trial.
    Beslija, S.
    Brodowicz, T.
    Greil, R.
    Inbar, M. J.
    Kahan, Z.
    Kaufman, B.
    Lang, I.
    Steger, G. G.
    Stemmer, S. M.
    Zielinski, C.
    Zvirbule, Z.
    CANCER RESEARCH, 2011, 71
12345